Demographic and baseline disease characteristics of enrolled study patients
| Placebo n=9 | Ianalumab 3 mg/kg n=6 | Ianalumab 10 mg/kg n=12 | |
| Age in years, median (range) | 50.0 (28, 58) | 49.0 (32, 56) | 58.5 (25, 70) |
| Female, n (%) | 7 (77.8) | 5 (83.3) | 11 (91.7) |
| Caucasian, n (%) | 9 (100.0) | 6 (100.0) | 12 (100.0) |
| Baseline ESSDAI | 10.0 (6, 19) | 12.5 (6, 31) | 10.0 (6, 18) |
| Baseline ESSPRI | 6.3 (3.0, 9.0) | 6.3 (4.7, 7.7) | 6.8 (3.0, 8.7) |
| Intake of oral corticosteroid daily dose in mg, median (range) | 5.0 (5.0, 5.0) | 5.0 (5.0, 7.5) | 2.5 (1.0, 9.0) |
ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index.